51 results
8-K
EX-99.1
LIANY
LianBio
13 Feb 24
LianBio Announces Completion of Strategic Review
7:04am
(Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian … on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. For more information, please
8-K
EX-99.1
LIANY
LianBio
20 Dec 23
LianBio Announces Departure of Chief Financial Officer
8:05am
company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial … to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing
8-K
EX-99.1
LIANY
LianBio
19 Dec 23
LianBio Announces Departure of Chief Executive Officer
4:26pm
company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief … medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio
8-K
EX-99.1
LIANY
LianBio
6 Dec 23
Regulation FD Disclosure
4:23pm
and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from … in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing
8-K
EX-99.1
LIANY
LianBio
1 Dec 23
Other Events
4:16pm
and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling … patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing
8-K
EX-99.1
qnp23q
13 Nov 23
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:17pm
8-K
EX-99.1
zib7n
30 Oct 23
LianBio Announces Topline Results from Phase 3 LIBRA Trial of
4:16pm
8-K
EX-99.1
d0r4kgk4awh
14 Aug 23
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
t16jgw4ew p218po
11 May 23
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
8dim8j
1 May 23
Regulation FD Disclosure
7:28am
8-K
EX-99.1
lshwpgnqmd1
26 Apr 23
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
8:07am
8-K
EX-99.1
hbu7c4kbby1ksd91g
21 Apr 23
Other Events
4:13pm
8-K
EX-99.1
6yfzrhd5cgiolq22
19 Dec 22
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
318wnz0oyg pt9hkim0
13 Dec 22
LianBio Announces President and Chief Strategy Officer Departure
5:03pm
S-3/A
sz6fw
9 Dec 22
Shelf registration (amended)
4:32pm